Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 15/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | INMT | O95050 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869238 | 0.74 | ACHE (0.49) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL15805617 | 0.72 | ACHE (0.50) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL16317909 | 0.72 | ACHE (0.50) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL15805653 | 0.72 | ACHE (0.50) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL8196022 | 0.67 | — | — | |
| SCHEMBL9216918 | 0.66 | ACHE (0.41) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL9540233 | 0.65 | ACHE (1.00) | ACHEUSP2BCHEMEN1ALDH1A1 | |
| SCHEMBL809425 | 0.64 | INMT (0.41) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL8969228 | 0.64 | ACHE (0.48) | ACHEUSP2INMTBCHEMEN1 | |
| SCHEMBL8969889 | 0.64 | ACHE (0.62) | ACHEUSP2BCHEMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20120083486-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-05 | — | — | US | disclosed |
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKI KAISHA | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059998-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | KIT, CHAT, BDNF | ACHE 4/4885USP2 3439/4885INMT 1261/4885 |
| US-20120083486-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | KIT, CHAT, BDNF | ACHE 4/4885USP2 3439/4885INMT 1261/4885 |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | PSEN1, GAP43, PSEN2 | ACHE 16/4885USP2 2378/4885INMT 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.